| 摘要 |
There are described compounds of the formula I (see formula I) in which R1 is (C1-C10)-alkyl, (C1-C8)-alkanoyl, (C6-C10)- aryl or Het, each of which can be substituted by halogen, -OH, -NH2, -NH-CO-R7, -O-CO-R7 and -N-(R8)2 where R7 = (C1-C6)-alkyl and R8, independently of one another, is hydrogen or (C1-C3)-alkyl or in which R1 is the radical of the formula II (see formula II) in which n is an integer from 3 to 10, m is zero to 3, R6, independently of one another, is (C1-C6)-alkyl which is optionally substituted by halogen or -NH-CO-R7, where R7 = (C1-C6)-alkyl, and X is absent or is (C1-C10)-alkyl, and R2, R3, R4 or R5, independently of one another, are hydrogen, (C1-C5)-alkyl, lithium, sodium, potassium or Si(R), where R = (C1-C5)-alkyl, and their physiologically tolerable salts, a process for preparation of these compounds of the formula I and their use as pharmaceuticals in the prophylaxis and treatment of osteoporosis and hypercalcemia.
|
